Dengue immunity can protect against Zika virus

November 13, 2017, La Jolla Institute for Allergy and Immunology
Zika virus has spread to many countries where dengue virus is endemic. Credit: La Jolla Institute for Allergy and Immunology

Manifestations of Zika virus (ZIKV) infection differ drastically. Sometimes they are catastrophic, most notably when they cause microcephaly in some babies born to infected mothers. At other times, they are mild and fleeting, suggesting that unknown factors temper Zika infections' severity. Recently, dengue virus emerged as a prime suspect because it shares many genetic and structural characteristics with ZIKV and is endemic in most of the regions affected by Zika's global spread.

A study published the November 13, 2017, issue of Nature Communications by La Jolla Institute for Allergy and Immunology (LJI) investigator Sujan Shresta, Ph.D., now addresses interplay between and ZIKV infections. It reports that mice rendered immune to dengue show "cross-protection" from subsequent Zika infection and then identifies specific types of immune T-cells capable of defending against both viruses. These revelations have profound implications for efforts to build a potent anti-Zika vaccine.

"In some parts of the world Zika is almost like a secondary infection. It has spread into Brazil/Latin America and is moving into places in Asia where people previously had dengue," says Shresta, an associate professor in LJI's Center for Infectious Disease. "Our new work suggests that vaccines targeting either virus could be engineered to induce both T cell and antibody responses effective to protect people in these areas."

When one encounters a pathogen in real life, two arms of the immune system spring into action to neutralize it. In the so-called humoral response, B-cells begin to secrete specific antibody proteins, which latch onto and neutralize pathogens in tissue or blood. Simultaneously, a cell-mediated immunity system also becomes active, deploying cytotoxic T-cells to directly recognize and kill pathogen-infected cells.

In theory, the ideal vaccine might mimic both antibody and T cell responses to block an infectious disease. But in truth, most (26 of 28 vaccines currently licensed for human use) stimulate primarily a B-cell or antibody response, which in many cases is sufficient. But Shresta's new work confirms what many vaccinologists are beginning to suspect, namely that protection against thus far intractable pathogens will likely require rallying both B-cells and T-cells.

Specifically, Shresta's team created the first "sequential" mouse model mimicking dengue-then-Zika infection. To do that, they first infected mice genetically vulnerable to to this family of viruses with . Those mice became sick, recovered from infection, and hence acquired immunity to dengue, presumably because viral infection had mobilized their immune B-cells, T-cells or both. The group then inoculated the same mice with ZIKV and waited to see if mice showed ZIKV symptoms. But overall, mice that had previously acquired dengue immunity showed protection against Zika, as evidenced by a reduced burden of ZIKV in blood and tissues, such as brain, liver or testis, compared to control mice not "pre-inoculated" against dengue.

"These experiments suggest that the reason that some people infected with Zika do not come down with disease is due to prior exposure to dengue," says Shresta. "This may explain why Zika is not passed to the unborn child of every pregnant woman in dengue-endemic countries exposed to virus."

In a different experiment, the scientists isolated cytotoxic T cells from the blood of dengue-immune mice and infused them into normal mice, a procedure known as adoptive T-cell transfer. When infused were then infected with ZIKV, they also showed disease resistance, supporting the idea that the T-cell arm of the immune system can do the heavy lifting against ZIKV .

Jinsheng Wen, Ph.D., a professor at Wenzhou Medical University in Wenzhou City, China, was the study's first author. Wen says the results from this work are a powerful lesson to vaccinologists currently wrestling with how to design an effective Zika vaccine: "Our work strongly suggests that a successful would need to include components to induce not only a B-cell response but also a T-cell response." Today, anti-dengue vaccines that primarily evoke antibody responses are in clinical trials or starting to be licensed in certain countries but show only moderate success. And, there are no approved Zika vaccines, although the US government is partnering with pharmaceutical companies to develop candidates.

Shresta hopes work like hers will guide those efforts. "Approved vaccines for many diseases work by inducing antibody responses. But now we are dealing with problematic diseases, like dengue and Zika for which we cannot rely solely on raising antibodies. Certain pathogens are likely to also require a T-cell response."

Explore further: Prior dengue or yellow fever exposure does not worsen Zika infection in monkeys

More information: Jinsheng Wen et al, Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge, Nature Communications (2017). DOI: 10.1038/s41467-017-01669-z

Related Stories

Prior dengue or yellow fever exposure does not worsen Zika infection in monkeys

August 4, 2017
Rhesus macaques previously infected with dengue or yellow fever viruses appear to be neither more nor less susceptible to severe infection with Zika virus, according to new research published in PLOS Pathogens.

Pre-existing immunity to dengue virus shapes Zika-specific T cell response

March 13, 2017
Although Zika and dengue are considered different virus "species," they are so closely related that the immune system treats Zika just like another version of dengue, report researchers at La Jolla Institute for Allergy and ...

Antibody protects against Zika and dengue, mouse study shows

September 25, 2017
Brazil and other areas hardest hit by the Zika virus - which can cause babies to be born with abnormally small heads - are also home to dengue virus, which is spread by the same mosquito species.

T cells join the fight against Zika

January 12, 2017
The worst of the global Zika virus outbreak may be over but many key questions remain, such as why the virus persists in certain tissues after the systemic infection has cleared; how does the immune system counteract the ...

More evidence that Zika mRNA vaccines can stop viral replication in mice

February 17, 2017
Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune ...

Study shows prior viral infections can make Zika infection worse

March 31, 2017
(Medical Xpress)—A team of researchers with the Icahn School of Medicine at Mount Sinai in New York City has found that mice who have survived a dengue or West Nile viral infection fare worse when subsequently infected ...

Recommended for you

Recent clinical trial finds tamsulosin not effective in kidney stone passage

June 18, 2018
The latest research into finding medications to aid the passage of ureteral or kidney stones has shown that tamsulosin is not effective for patients across the board. Previously approved to help men experiencing enlarged ...

Research finds new way to determine protection of Men B vaccine against different strains

June 18, 2018
Researchers at the University of Leicester and Meningococcal Reference Unit have developed a new approach to assess the effectiveness of the Men B vaccine, Bexsero, against different strains that cause meningococcal meningitis ...

Novel molecular target to prevent scarring of the lung blood vessels identified

June 13, 2018
Pulmonary arterial hypertension, a severe form of cardiopulmonary disease in which the arteries that transport blood from the heart to the lungs become thickened, constricted, and scarred, is a disease for which there is ...

Lineage of TB traced and compared to early human migration

June 13, 2018
A team of researchers from the University of Wisconsin, the University of Iowa and the Norwegian Institute of Public Health has carried out genetic studies of tuberculosis to learn more about its lineage and to compare it ...

Fast-acting cholera vaccine could curb outbreaks

June 13, 2018
A tricked-out cholera vaccine starts protecting against the deadly disease within a day, experiments in rabbits suggest. The rapid protection offered by this designer vaccine may one day limit the spread of cholera outbreaks, ...

Finally, hope for a syphilis vaccine

June 12, 2018
Despite efforts to eradicate it, syphilis is on the rise. Until now, most health agencies focused on treating infected people and their sex partners but new discoveries may make a vaccine possible, UConn Health researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.